Table 1A.
Baseline Characteristics of the Four Treatment Groups, Intention to Treat (N=45)
| Placebo | Paroxetine | Fluconazole | Paroxetine + Fluconazole | |
|---|---|---|---|---|
|
| ||||
| n=11 | n=11 | n=11 | n=12 | |
|
| ||||
| Age-Years/median (IQR) | 49 (45, 58) | 53 (48, 59) | 51 (48, 56) | 50.5 (47.5, 53.5) |
|
| ||||
| Education-Years: Median (IQR) | 12 (12, 13) | 12 (12, 14) | 12 (12, 14) | 11.5 (10, 13.5) |
|
| ||||
| Gender (% Male) | ||||
| Male | 9 (81.1) | 9 (81.8) | 10 (90.9) | 4 (33.3) |
| Female | 1 (9.1) | 2 (18.2) | 1 (9.1) | 7 (58.3) |
| Trans | 1 (9.1) | 0 | 0 | 1 (8.3) |
|
| ||||
| Race (% African-American) | 9 (81.8) | 8 (72.7) | 10 (90.9) | 10 (83.3) |
|
| ||||
| CD4 count: Median (IQR) | 461 (359, 520) | 620 (417, 849) | 504 (408, 553) | 534.5 (341, 627) |
|
| ||||
| Plasma HIV RNA-copies/ml: Median (IQR) | 0 (0,0) | 0 (0,0) | 0 (0,0) | 0 (0,78) |
|
| ||||
| Plasma HIV RNA: % <50 copies/ml | 10 (90.9) | 9 (81.8) | 11 (100) | 7 (58.3) |
|
| ||||
| Hepatitis C serology: % positive | 8 (72.7) | 3 (27.3) | 7 (63.6) | 6 (50.0) |
|
| ||||
| CES-D Mean( IQR) | 10 (4.20) | 2 (0.6) | 18 (6.24) | 8.5 (6.5, 12.5) |
IQR, interquartile range (25th and 75th percentile)
CES-D (Center for Epidemiological Studies-Depression scale